UGT1A1 and colorectal cancer: SCO-101 has previously been studied together with chemotherapy in patients with colorectal cancer, where the compound counteracts resistance to irinotecan by inhibiting the drug efflux pump ABCG2 and the metabolic liver enzyme UGT1A1 [8].